Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Onvansertib treatment overcomes olaparib resistance in high-grade ovarian carcinomas.
Chiappa M, Decio A, Guarrera L, Mengoli I, Karki A, Yemane D, Ghilardi C, Scanziani E, Canesi S, Barbera MC, Craparotta I, Bolis M, Fruscio R, Grasselli C, Ceruti T, Zucchetti M, Patterson JC, Lu RA, Yaffe MB, Ridinger M, Damia G, Guffanti F. Chiappa M, et al. Among authors: decio a. Cell Death Dis. 2024 Jul 22;15(7):521. doi: 10.1038/s41419-024-06894-1. Cell Death Dis. 2024. PMID: 39039067 Free PMC article.
Tumor progression and metastatic dissemination in ovarian cancer after dose-dense or conventional paclitaxel and cisplatin plus bevacizumab.
Bizzaro F, Falcetta F, D'Agostini E, Decio A, Minoli L, Erba E, Alessandro Peccatori F, Scanziani E, Colombo N, Zucchetti M, Bani MR, Ubezio P, Giavazzi R. Bizzaro F, et al. Among authors: decio a. Int J Cancer. 2018 Nov 1;143(9):2187-2199. doi: 10.1002/ijc.31596. Epub 2018 Aug 7. Int J Cancer. 2018. PMID: 29752717 Free article.
The PARP1 Inhibitor AZD5305 Impairs Ovarian Adenocarcinoma Progression and Visceral Metastases in Patient-derived Xenografts Alone and in Combination with Carboplatin.
Dellavedova G, Decio A, Formenti L, Albertella MR, Wilson J, Staniszewska AD, Leo E, Giavazzi R, Ghilardi C, Bani MR. Dellavedova G, et al. Among authors: decio a. Cancer Res Commun. 2023 Mar 27;3(3):489-500. doi: 10.1158/2767-9764.CRC-22-0423. eCollection 2023 Mar. Cancer Res Commun. 2023. PMID: 36994441 Free PMC article.
Development of a HPLC-MS/MS Method to Assess the Pharmacokinetics and Tumour Distribution of the Dimethylarginine Dimethylaminohydrolase 1 Inhibitors ZST316 and L-257 in a Xenograft Model of Triple-Negative Breast Cancer in Mice.
Ceruti T, Frapolli R, Ghilardi C, Decio A, Dellavedova G, Tommasi S, Zucchetti M, Mangoni AA. Ceruti T, et al. Among authors: decio a. Molecules. 2023 Dec 13;28(24):8056. doi: 10.3390/molecules28248056. Molecules. 2023. PMID: 38138547 Free PMC article.
Tumor microenvironment-induced FOXM1 regulates ovarian cancer stemness.
Battistini C, Kenny HA, Zambuto M, Nieddu V, Melocchi V, Decio A, Lo Riso P, Villa CE, Gatto A, Ghioni M, Porta FM, Testa G, Giavazzi R, Colombo N, Bianchi F, Lengyel E, Cavallaro U. Battistini C, et al. Among authors: decio a. Cell Death Dis. 2024 May 28;15(5):370. doi: 10.1038/s41419-024-06767-7. Cell Death Dis. 2024. PMID: 38806454 Free PMC article.
43 results